Suzhou Cost Of Revenue from 2010 to 2024

688137 Stock   36.93  0.40  1.07%   
Suzhou Novoprotein's Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Cost Of Revenue is expected to dwindle to about 37.1 M. From 2010 to 2024 Suzhou Novoprotein Cost Of Revenue quarterly data regression line had arithmetic mean of  24,345,217 and r-squared of  0.56. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
37.3 M
Current Value
37.1 M
Quarterly Volatility
8.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Suzhou Novoprotein financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Suzhou Novoprotein's main balance sheet or income statement drivers, such as Net Interest Income of 28.2 M, Interest Income of 32 M or Interest Expense of 2.9 M, as well as many indicators such as . Suzhou financial statements analysis is a perfect complement when working with Suzhou Novoprotein Valuation or Volatility modules.
  
This module can also supplement various Suzhou Novoprotein Technical models . Check out the analysis of Suzhou Novoprotein Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Suzhou Stock

Suzhou Novoprotein financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Novoprotein security.